Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Unknown 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 62CNS 8Gastrointestinal 4Tumor-Agnostic 3Head & Neck 2Breast 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
icotinib × Gastrointestinal × Clear all
NCT01855854 2019-07-05

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Betta Pharmaceuticals Co., Ltd.

Phase 2 Completed
54 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02375581 2016-03-22

Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

First People's Hospital of Hangzhou

Phase 2 Unknown
130 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02024633 2015-07-15

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡